Nuvalent (NUVL) AI Stock Analysis

• Market Cap: $7.46B
• Dividend Yield: N/A
• Average Volume (3M): 491.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.98
• Revenue Growth: N/A
• EPS Growth: -52.84%
• Country: US
• Employees: 162
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.58
• Shares Outstanding: 67,271,460
• 10 Day Avg. Volume: 518,998
• 30 Day Avg. Volume: 491,612
• PEG Ratio: -0.35
• Price to Book (P/B): 5.86
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -26.57
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -21.31
• 1Y Price Target: $142.31
• Price Target Upside: 42.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14
• EPS Forecast (FY): -5.52
• Revenue Forecast (FY): $13.91M

• Rating: 51 Neutral
• Price Target: $102.00 ▲(1.78% Upside)
• Action: Reiterated Date: 02/28/26
• Date: Action: Reiterated 02/28/26

The score is driven primarily by a strong, debt-free balance sheet that provides funding flexibility, but is materially constrained by the lack of revenue, sharply expanding losses, and accelerating cash burn. Technical indicators are neutral-to-mixed and do not meaningfully offset the fundamental cash flow risk, while valuation metrics provide limited support due to negative earnings and no dividend data.

Positive Factors

Debt-free, substantial equity base

Zero reported debt and roughly $1.25B of equity provide durable financial flexibility to fund multi-year drug development, absorb clinical setbacks, and invest in registration and launch activities without immediate leverage, supporting long-term R&D continuity.

Multi-year cash runway

Reported $1.4B in liquid resources and management’s stated runway into 2029 materially reduce near-term financing pressure, allowing the company to progress late-stage programs, seek approvals, and build commercial capabilities before needing additional capital.

Focused precision-oncology pipeline

Targeting genetically defined tumors and unmet needs like resistance and CNS metastases positions the company in a high-value, durable niche; narrow, biomarker-driven indications can enable efficient trials, clearer regulatory paths, and differentiated commercial positioning.

Negative Factors

No product revenue (clinical-stage)

Absence of commercial revenue means all progress depends on R&D success and external funding; lacking proven commercial cash flows increases long-term execution and financing risk and delays ability to demonstrate sustainable profitability or unit economics.

Accelerating cash burn and negative FCF

Steadily worsening free cash flow and persistent negative operating cash flow elevate the probability the company will need additional capital before commercialization, creating dilution risk and tighter prioritization across programs over the medium term.

Outsourced royalty reduces future revenue capture

Selling a royalty interest locks a portion of future product revenue to a third party, permanently reducing net sales retained by equity holders and constraining upside per successful product, which affects long-term revenue economics and shareholder returns.

Nuvalent Business Overview & Revenue Model

Company Description

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Nuvalent makes money through the development and commercialization of its proprietary drug candidates. The company's revenue model primarily involves bringing its pipeline of targeted cancer therapies through clinical trials and regulatory approval to eventually enter the market. Once approved, these therapies can generate income through sales, licensing agreements, and potential partnerships with larger pharmaceutical companies. Additionally, Nuvalent may engage in collaborations that provide milestone payments and royalties, contributing to its earnings.

Nuvalent Financial Statement Overview

Summary

Balance sheet strength (zero debt and sizable equity) supports continued R&D, but this is offset by no revenue, rapidly widening net losses, and accelerating negative free cash flow that increases reliance on existing capital and future funding.

Income Statement

The company reports no revenue across the provided annual periods, which is typical for an early-stage biotech but limits visibility into operating leverage. Losses have widened meaningfully over time (net loss from about $14.6M in 2020 to about $425.4M in 2025), indicating a rising expense base. Profitability remains deeply negative (negative EBIT and net income each year), with the key positive being that the magnitude of investment suggests active pipeline progress—but the financials show no near-term path to earnings without revenue inflection.

Balance Sheet

The balance sheet is a clear strength: total debt is reported at $0 from 2021–2025, and stockholders’ equity has grown substantially to about $1.25B by 2025 (assets about $1.41B). This low-leverage profile provides flexibility to fund R&D and absorb operating losses. The main weakness is economic profitability: returns on equity are negative in recent years, reflecting that capital is being consumed rather than generating profits.

Cash Flow

Cash generation is the primary pressure point: operating cash flow and free cash flow are negative every year, with cash burn accelerating (free cash flow from about -$40.0M in 2021 to about -$275.2M in 2025). While 2025 shows positive free cash flow growth (less favorable year-over-year comparison improving), overall cash usage remains heavy and rising. Cash flow trends imply continued dependence on the balance sheet (cash/equity) and potential external funding if burn rates persist.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-10.48M	0.00	-126.22M	-86.11M	-45.82M
Net Income	-425.38M	-260.76M	-126.22M	-81.85M	-46.34M
Balance Sheet
Total Assets	1.41B	1.14B	732.38M	482.46M	293.82M
Cash, Cash Equivalents and Short-Term Investments	1.37B	1.12B	719.90M	472.16M	288.11M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	164.37M	71.96M	31.82M	19.48M	8.79M
Stockholders Equity	1.25B	1.07B	700.56M	462.98M	285.04M
Cash Flow
Free Cash Flow	-275.21M	-185.06M	-99.74M	-64.97M	-40.00M
Operating Cash Flow	-275.21M	-185.06M	-99.74M	-64.97M	-40.00M
Investing Cash Flow	-124.08M	-573.51M	-143.53M	-10.66M	-220.03M
Financing Cash Flow	515.34M	568.88M	336.85M	248.92M	318.22M

Nuvalent Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 100.22
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUVL, the sentiment is Negative. The current price of 100.22 is below the 20-day moving average (MA) of 102.80, below the 50-day MA of 103.40, and above the 200-day MA of 89.83, indicating a neutral trend. The MACD of -0.51 indicates Positive momentum. The RSI at 43.85 is Neutral, neither overbought nor oversold. The STOCH value of 33.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NUVL.

Nuvalent Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TGTX	61 Neutral	$4.61B	9.62	102.75%	―	100.88%	―
RNA	54 Neutral	―	―	-32.44%	―	106.27%	-43.90%
AXSM	52 Neutral	$8.39B	-49.60	-252.11%	―	65.83%	28.50%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NUVL	51 Neutral	$7.46B	-17.19	-36.70%	―	―	-52.84%
CYTK	50 Neutral	$7.67B	-9.72	―	―	2609.26%	-17.08%

Nuvalent Corporate Events

Nuvalent’s Royalty Interest Acquired by Royalty Pharma

Royalty Pharma plc has acquired a royalty interest in Nuvalent‘s investigational products, neladalkib and zidesamtinib, for up to $315 million from an undisclosed third party. This acquisition involves a 1.5% royalty on net sales, potentially impacting Nuvalent’s financial operations and market positioning.

The most recent analyst rating on (NUVL) stock is a Buy with a $140.00 price target. To see the full list of analyst forecasts on Nuvalent stock, see the NUVL Stock Forecast page.

Ron Squarer Joins Nuvalent Board as Independent Director

On December 9, 2025, Matthew Shair, Ph.D., resigned from the board of directors of Nuvalent, Inc., a decision not due to any disagreement with the company’s operations or policies. Subsequently, on December 10, 2025, Ron Squarer was elected as a new independent director, with compensation including stock options and restricted stock units valued at $600,000, marking a strategic addition to the board.

The most recent analyst rating on (NUVL) stock is a Buy with a $128.00 price target. To see the full list of analyst forecasts on Nuvalent stock, see the NUVL Stock Forecast page.